Tecfidera

DRUG6 trials

Conditions

Multiple SclerosisMultiple Sclerosis (MS)Relapsing-Remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 1

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

CompletedNCT04022473

Banner Life Sciences LLCMultiple Sclerosis

Start: 2019-07-07End: 2019-10-19Updated: 2020-01-18

Phase 2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

TerminatedNCT02975349

EMD Serono Research & Development Institute, Inc.Relapsing-remitting Multiple Sclerosis

Start: 2017-03-07End: 2024-04-02Updated: 2025-05-14

Phase 3

Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)

CompletedCTIS2023-505632-35-00

Biogen Idec Research LimitedRelapsing-Remitting Multiple Sclerosis

Start: 2014-07-24End: 2025-07-08Target: 37Updated: 2024-10-17

Phase 4

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

CompletedNCT02739542

University of Texas Southwestern Medical CenterMultiple Sclerosis (MS)

Start: 2016-03-19End: 2021-03-31Updated: 2022-05-11

Unknown Phase

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

TerminatedNCT02218879

Yale UniversityMultiple Sclerosis

Start: 2014-08-31End: 2016-04-30Updated: 2016-09-05

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

CompletedNCT02823951

IMS HEALTH GmbH & Co. OHGRelapsing-remitting Multiple Sclerosis

Start: 2016-02-29End: 2018-02-28Updated: 2018-03-01

2024-02-0915 citations

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

Multiple Sclerosis Journal2023-08-254 citations

A Plain Language Summary of What Clinical Studies Can Tell Us About the Safety of Evobrutinib – a Potential Treatment for Multiple Sclerosis

Neurodegenerative Disease Management2023-06-223 citations

Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008)

Neurology2023-04-253 citations

Neurofilament Light Chain Levels and Disease Activity During Long-Term Treatment of Relapsing Multiple Sclerosis with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (P1-3.011)

Neurology2023-04-252 citations

Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Patients with Relapsing Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib: An Update (P2-3.017)

Neurology2023-04-25

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Journal of Neurology Neurosurgery & Psychiatry2022-11-2329 citations

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome

Annals of Neurology2022-11-19111 citations

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase<scp>II</scp>relapsing multiple sclerosis study

Clinical and Translational Science2022-09-2014 citations

Brain-homing B cells in multiple sclerosis: association with Bruton’s tyrosine kinase and targeting by evobrutinib (4095)

Neurology2021-04-131 citations

056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study

Journal of Neurology Neurosurgery & Psychiatry2019-07-012 citations

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

New England Journal of Medicine2019-05-10307 citations